Claims for Patent: 8,486,957
✉ Email this page to a colleague
Summary for Patent: 8,486,957
Title: | Chemotherapeutic for inducing an MSH2-dependent apoptotic pathway |
Abstract: | A method of treating cancer in a subject in need thereof comprises administering said subject reserpine, yohimbine, an analog thereof, or a pharmaceutically acceptable salt or prodrug thereof, in an amount effective to treat the cancer. Compounds and compositions useful for carrying out the method are also described. |
Inventor(s): | Salsbury, Jr.; Freddie R. (Winston-Salem, NC), Scarpinato; Karin D. (Clemmons, NC), King; S. Bruce (Walnut Cove, NC) |
Assignee: | Wake Forest University Health Sciences (Winston-Salem, NC) |
Application Number: | 12/711,306 |
Patent Claims: | 1. A compound of Formula Ia: ##STR00015## wherein: R.sub.1 is methoxy; R.sub.2is: ##STR00016## where each R' is independently selected from H, OH, OCH.sub.3, and COOH,
subject to the proviso that at least one R' is COOH; R.sub.3 is hydroxy or loweralkoxy, R.sub.4 is --C(O)OR' or --NHC(O)OR', where R' is H or loweralkyl; or a pharmaceutically acceptable salt or ester thereof.
2. A composition comprising a compound of claim 1 in a pharmaceutically acceptable carrier. 3. The composition of claim 2, further comprising at least one additional chemotherapeutic agent. 4. The composition of claim 3, wherein said additional chemotherapeutic agent is selected from the group consisting of androgens, asparaginase, azathioprine, 5-azacitidine, BCG, bleomycin, busulfan, carbetimer, carboplatin chlorambucil, cisplatin, oxaliplatin, corticosteroids, cyclophosphamide, cytarabine, dacarbazine, dactinomicin, daunomycin, doxorubicin, epirubicin, estrogens, etoposide, fadrazole, 5-flurouracil, gemcitabine, hydroxyurea, ifosfamide, interferon alpha, interferon beta, interferon gamma, an interleukin, isotretinoin, lomustine, melphalan, 6-mercaptopurine, methotrexate, mitomycin-c, mitotane, mitoxantrone, paclitaxel, pentostatin, procabazine, progestins, rituximab, streptozocin, tamoxifen, taxotere, teniposide, thioguanine, thiotepa, topotecan, toremifene, tretinoin, uracil mustard, vinblastine, vincristine and vinorelbine. 5. The compound of claim 1 selected from the group consisting of: ##STR00017## and pharmaceutically acceptable salts thereof. |
Details for Patent 8,486,957
Applicant | Tradename | Biologic Ingredient | Dosage Form | BLA | Approval Date | Patent No. | Expiredate |
---|---|---|---|---|---|---|---|
Recordati Rare Diseases, Inc. | ELSPAR | asparaginase | For Injection | 101063 | 01/10/1978 | ⤷ Try a Trial | 2027-08-24 |
Genentech, Inc. | RITUXAN | rituximab | Injection | 103705 | 11/26/1997 | ⤷ Try a Trial | 2027-08-24 |
Idec Pharmaceuticals Corp. | RITUXAN | rituximab | Injection | 103737 | 02/19/2002 | ⤷ Try a Trial | 2027-08-24 |
Genentech, Inc. | RITUXAN HYCELA | rituximab and hyaluronidase human | Injection | 761064 | 06/22/2017 | ⤷ Try a Trial | 2027-08-24 |
>Applicant | >Tradename | >Biologic Ingredient | >Dosage Form | >BLA | >Approval Date | >Patent No. | >Expiredate |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.